2-chloro-N-(1-(3-methyl-4-(6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6H-pyrrolo[3,4-g]quinolin-7(8H)-yl)benzyl)cyclopropylcarbamoyl)benzenesulfonamide | 1064195-64-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-chloro-N-(1-(3-methyl-4-(6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6H-pyrrolo[3,4-g]quinolin-7(8H)-yl)benzyl)cyclopropylcarbamoyl)benzenesulfonamide
• 英文别名: 1-(2-chlorophenyl)sulfonyl-3-[1-[[3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-8H-pyrrolo[3,4-g]quinolin-7-yl]phenyl]methyl]cyclopropyl]urea
• CAS: 1064195-64-7
• 化学式: C₃₃H₂₇ClF₆N₄O₆S
• 分子量: 757.11
• InChiKey: LKOISZAXLYFGBX-UHFFFAOYSA-N

物化性质

• 密度：
  1.58±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  51
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  135
• 氢给体数：
  2
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  4-氨基-3-甲基苯甲酸甲酯 在 titanium(IV) isopropylate 、 三乙基硅烷 、 sodium tetrahydroborate 、 dimethyl sulfide borane 、 水 、 溶剂黄146 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-chloro-N-(1-(3-methyl-4-(6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6H-pyrrolo[3,4-g]quinolin-7(8H)-yl)benzyl)cyclopropylcarbamoyl)benzenesulfonamide
  参考文献：
  名称：

  Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor

  摘要：

  Two new series of EP4 antagonists based on naphthalene/quinoline scaffolds have been identified as part of our on-going efforts to develop treatments for inflammatory pain. One series contains an acidic sulfonylurea pharmacophore, whereas the other is a neutral amide. Both series show subnanomolar intrinsic binding potency towards the EP4 receptor, and excellent selectivity towards other prostanoid receptors. While the amide series generally displays poor pharmacokinetic parameters, the sulfonylureas exhibit greatly improved profile. MF-592, the optimal compound from the sulfonylurea series, has a desirable overall preclinical profile that suggests it is suitable for further development. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.014

文献信息

• NAPHTHALENE AND QUINOLINE SULFONYLUREA DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
  申请人：Merck Frosst Canada Ltd.

  公开号：EP2125724A1

  公开（公告）日：2009-12-02
• US8003661B2
  申请人：——

  公开号：US8003661B2

  公开（公告）日：2011-08-23
• [EN] NAPHTHALENE AND QUINOLINE SULFONYLUREA DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE NAPHTALÈNE ET QUINOLÉINE SULFONYLURÉE COMME ANTAGONISTES DU RÉCEPTEUR EP4
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2008116304A1

  公开（公告）日：2008-10-02

  [EN] The invention is directed to naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.
  [FR] L'invention porte sur des dérivés de naphtalène et quinoléine sulfonylurée en tant qu'antagoniste du récepteur EP4, utiles pour le traitement de maladies ou états à médiation par EP4, telles que la douleur aiguë et chronique, l'ostéoarthrite, l'arthrite rhumatoïde et le cancer. L'invention porte également sur des compositions pharmaceutiques et des procédés d'utilisation.
• Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor
  作者：Jason D. Burch、Julie Farand、John Colucci、Claudio Sturino、Yves Ducharme、Richard W. Friesen、Jean-François Lévesque、Sébastien Gagné、Mark Wrona、Alex G. Therien、Marie-Claude Mathieu、Danielle Denis、Erika Vigneault、Daigen Xu、Patsy Clark、Steve Rowland、Yongxin Han

  DOI：10.1016/j.bmcl.2010.12.014

  日期：2011.2

  Two new series of EP4 antagonists based on naphthalene/quinoline scaffolds have been identified as part of our on-going efforts to develop treatments for inflammatory pain. One series contains an acidic sulfonylurea pharmacophore, whereas the other is a neutral amide. Both series show subnanomolar intrinsic binding potency towards the EP4 receptor, and excellent selectivity towards other prostanoid receptors. While the amide series generally displays poor pharmacokinetic parameters, the sulfonylureas exhibit greatly improved profile. MF-592, the optimal compound from the sulfonylurea series, has a desirable overall preclinical profile that suggests it is suitable for further development. (C) 2010 Elsevier Ltd. All rights reserved.